NGIg

By Dr. Rasha Msallam

About NGIG

Elevating Immunological Research: NGIG’s Commitment

About the Founder

Dr. Rasha Msallam, founder of NGIg Consultancy, has over 15 years of expertise in preclinical and translational immunology.

Our Mission

NGIg Consultancy was established to integrate advanced immunological knowledge into diverse biomedical research projects. We provide an unbiased perspective, identifying and addressing gaps in scientific research. Our collaboration with scientists, clinicians, and both public and private healthcare organizations aims to produce actionable research outcomes and advance projects beyond the laboratory.

Our Approach

NGIg Consultancy supports projects at any stage, from initial concept through data analysis, outcome development, and original article writing. Our goal is to advance research effectively to the next phase.

World's leading research institute, with a team of experts and scientists devoted
to development of new discoveries in the field
of translational and clinical neuroscience.

Scope: Unravel The Immunity of Pediatric Allergies: “The Story Starts in The Womb” (Period 24 months)

Job to be done

Using novel genetic technologies such as RNA sequencing (scRNA).

Establishment of bio-bank of fetal tissues in collaboration with the ministry of health in Singapore and the clinicians at the KK Women’s and Children’s Hospital

Development of state-of-art integrating framework to analyze metadata and its biological significance in time-saving manner.

Solutions

Developing a preclinical model to identify the mechanism of developing allergic diseases in newborn.

Establish a library of novel bio-markers as an early-detection assessment of allergic diseases.

Identify the environmental factors in developing asthma and skin allergies.

Results

My contribution led to Designing a framework to investigate the link of developing atopic dermatitis in children born for atopic mothers. The collaboration was funded by Telethon Kids Institutes(Australia) (AUD 100,000) for a proof-of-concept study.

Scope: Development of biomarkers for an accurate and less invasive management of Breast cancer (Period: 6 months)

Job to be done

Correlation of the blood tests, clinical history, and the pathology reports.

Developing a personalized metrics for an accurate diagnosis.

Applied analytical methods, in collaboration with computer scientists to develop an accurate predictive diagnostic tools in breast cancer

Solutions

Establishing a pipeline to process biological samples.


Training bioinformaticians to understand the biology of breast cancer and collaborate to translate the statistics outcomes into applicable
Identify the environmental factors in developing asthma and skin allergies.

Results

The delivered results helped to:

Build a reference framework for clinicians and to apply personalized therapy instead of standard care protocols.

The potential outcomes will decrease the unnecessary surgeries and identify a specific immunotherapy to be applied with minimal toxicity and undesirable side effects.

Scope: Discovery of novel and quantitative imaging agents to interrogate inflammation in brain, cancer, and infectious disease (ongoing)

Job to be done

Collaboration with biochemists, virologists, and clinicians to identify the probe of interests.

Evaluate the radioactivity and the potential toxicity of the developed probes.

Integrating cutting-edge technology in proteomics

Solutions

Establishing a pipeline to process biological samples.

Training bioinformaticians to understand the biology of breast cancer and collaborate to translate the statistics outcomes into applicable

Identify the environmental factors in developing asthma and skin allergies.

Results

The delivered results helped to:

Publication of 3 articles, and another 3 papers are in preparation. NGIg is the solely consultant for all these papers.
The obtained results helped to acquire phase 2 of a governmental grant (SGD 10 million)
Developing an immuno-monitoring pipeline for potential integration in the oncology department at Singaporean general hospital (SGH)
The collaboration is still ongoing with patents and publications in the pipeline

As Featured In